Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
03 Januar 2024 - 2:00PM
Business Wire
- Only FDA-Approved As-Needed Treatment For The Approximately
6 Million Premenopausal Women Who Suffer From Hypoactive Sexual
Desire Disorder (HSDD)
- Vyleesi® has experienced 8 Consecutive Quarters of
Double-Digit Prescription Growth
- Acquisition Adds Another Commercial Stage, Patent Protected
Product to Cosette’s Rapidly Expanding Women’s Health
Portfolio
Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty
pharmaceutical company with a focus on women’s health and
cardiovascular medicines, has completed the acquisition of Vyleesi®
from Palatin Technologies, Inc. (NYSE: PTN), which includes 5
Orange Book listed patents with protection up to 2041. Palatin and
Cosette will ensure continued patient and healthcare professional
access to Vyleesi® throughout the transition period.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240103181501/en/
Vyleesi (Photo: Business Wire)
“This acquisition highlights Cosette’s continued focus on
improving women’s health, and our dedication to increasing
awareness and education,” stated Apurva Saraf, President and CEO of
Cosette. “Our strong commercial capabilities, coupled with our
commitment to partnering with the women’s health community will
drive improved access to Vyleesi® for the millions of women who
suffer from HSDD.”
HSDD is the most common female sexual dysfunction condition in
the U.S., impacting approximately 6 million premenopausal women.
HSDD is defined as a persistent or recurrent absence of sexual
fantasies and desire for sexual activity, which causes marked
personal distress or interpersonal difficulties.
“HSDD has been a recognized medical condition for over 40 years,
but is widely underdiagnosed and undertreated,” said Rachel Rubin,
M.D., Urologist and Sexual Medicine Specialist. “Vyleesi® is a
welcome tool in our biopsychosocial toolbox. It is a novel and
effective treatment option for HSDD that can be self-administered
as needed in anticipation of sexual activity. Women with HSDD
should not ignore or justify their symptoms and should talk to
their healthcare provider about reclaiming their sexual
desire.”
Cosette is committed to working with healthcare professionals to
help ensure women with HSDD have access to Vyleesi®. Cosette offers
patients the ability to connect with a physician through a
telemedicine option. Patients and providers can learn more about
HSDD and Vyleesi®, including Important Safety Information, at
www.vyleesi.com.
About Cosette Pharmaceuticals:
Cosette Pharmaceuticals, Inc. (“Cosette”) is a US-based, fully
integrated pharmaceutical company with a fast-growing portfolio of
branded pharmaceuticals consisting of products in women’s health,
cardiology and dermatology. Cosette has a long history in quality
manufacturing of complex dosage forms including topical creams,
ointments, oral liquids/solutions and suppositories. Cosette has
corporate and manufacturing facilities in New Jersey and North
Carolina and is supported by 300+ dedicated employees across all
functional areas. Cosette is backed by Avista Capital Partners, a
healthcare focused private equity firm.
Visit www.cosettepharma.com and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103181501/en/
Serge Ilin-Schneider: bd@cosettepharma.com Kevin Hickey:
sales@cosettepharma.com
Palatin Technologies (AMEX:PTN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Palatin Technologies (AMEX:PTN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024